Device makers, like pharmaceutical manufacturers, have long recognized that their success depends upon making their products known to physicians who will prescribe or recommend the use of their particular product.
In addition to their ability to influence current product use, physicians also are in the best position to conduct or oversee research that may expand future market share, including identifying additional clinical uses or adaptations for a product — some of which may not yet be approved by the U.S. Food and Drug Administration (FDA).
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc. This appeared in both Health Law360 and Competition Law360.
Author(s)
Related Insights
July 25, 2025
Foley Viewpoints
Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition
We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this…
July 24, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…